TITLE

Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study

AUTHOR(S)
Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge
PUB. DATE
October 2012
SOURCE
PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm³ compared to untreated controls. When the results of two large clinical trials, ESPRIT and SILCAAT, showed no clinical benefit from IL-2 therapy, IL-2 administration was halted in STALWART. Because IL-2 recipients in STALWART experienced a greater number of opportunistic disease (OD) or death and adverse events (AEs), participants were asked to consent to an extended follow-up phase in order to assess persistence of IL-2 effects. Methodology: Participants in this study were followed for clinical events and AEs every 4 months for 24 months. Unadjusted Cox proportional hazards models were used to summarize death, death or first OD event, and first grade 3 or 4 AE. Principal Findings: A total of 267 persons were enrolled in STALWART (176 randomized to the IL-2 arms and 91 to the no therapy arm); 142 individuals in the IL-2 group and 80 controls agreed to enter the extended follow-up study. Initiation of continuous ART was delayed in the IL-2 groups, but once started, resulted in similar CD4+ cell and viral load responses compared to controls. The hazard ratios (95% CI) for IL-2 versus control during the extension phase for death or OD, grade 3 or 4 AE, and grade 4 AE were 1.45 (0.38, 5.45), 0.43 (0.24, 1.63) and 0.20 (0.04, 1.03), respectively. The hazard ratios for the AE outcomes were significantly lower during the extension than during the main study. Conclusions: Adverse events associated with IL-2 cycling did not persist upon discontinuation of IL-2. The use of IL-2 did not impact the subsequent response to initiation of cART.
ACCESSION #
83523680

 

Related Articles

  • Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. Mosha, Fausta; Ledwaba, Johanna; Ndugulile, Faustine; Ng'ang'a, Zipora; Nsubuga, Peter; Morris, Lynn; Kasubi, Mabula; Swai, Andrew; Vercauteren, Jurgen; Vandamme, Anne-Mieke // Journal of Infection in Developing Countries;Jul2014, Vol. 8 Issue 7, p845 

    Introduction: In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. Methodology: A cross-sectional study of a cohort of 150...

  • Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection. Molina, Jean-Michel // Drugs;2008, Vol. 68 Issue 5, p567 

    Early versions of highly-active antiretroviral therapy (HAART) characteristically involved complicated combinations of different drugs, which were taken as varying numbers of pills and as multiple doses each day. With the recent availability of once-daily treatment drugs, simpler regimens are...

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • Modelling Treatment Response Could Reduce Virological Failure in Different Patient Populations. Revell, Andrew D.; Wang, Dechao; d'Ettorre, Gabriella; DE Wolf, Frank; Gazzard, Brian; Ceccarelli, Giancarlo; Gatell, Jose; Pérez-elías, María Jésus; Vullo, Vincenzo; Montaner, Julio S.; Lane, H. Clifford; Larder, Brendan A. // Journal of AIDS & Clinical Research;Special2012, Vol. 3 Issue S, Special section p1 

    Background: HIV drug resistance can cause viral re-bound in patients on combination antiretroviral therapy, requiring a change in therapy to re-establish virological control. The RDI has developed computational models that predict response to combination therapy based on the viral genotype,...

  • Long-Term Quality-of-Life Outcomes Among Adults Living with HIV in the HAART Era: The Interplay of Changes in Clinical Factors and Symptom Profile. Burgoyne, Robert W.; Rourke, Sean B.; Behrens, Dean M.; Salit, Irving E. // AIDS & Behavior;Jun2004, Vol. 8 Issue 2, p151 

    Changes in quality-of-life perceptions and their relations to clinical status for 41 adult outpatients living with HIV/AIDS were assessed over a 4-year period. Clinical variables and quality-of- life (Medical Outcomes Study Short-Form-36) ratings were measured in three waves (T1, 1997; T2, 1999;...

  • Characteristics of Circulating Immune Complexes in HIV-Infected Patients with Different Viral Load. Korolevskaya, L.; Shmagel, K.; Shmagel, N. // Bulletin of Experimental Biology & Medicine;Aug2015, Vol. 159 Issue 4, p469 

    Serum concentration of antiviral antibodies was measured in HIV-infected patients with different viral load. It was found that higher concentrations of HIV-antigens correspond to higher titer of antiviral antibodies. Circulating immune complexes were isolated from patients' serum to estimate...

  • The Failure of Medical Science To Prevent and To Adequately Treat HIV/AIDS: An Orthomolecular Opportunity. Foster, Harold D. // Journal of Orthomolecular Medicine;2008 1st Quarter, Vol. 23 Issue 1, p6 

    The article focuses on the inability of medical science to prevent and cure HIV/AIDS. The "Journal of Orthomolecular Medicine" proved the inaccuracy of the conventional model of how HIV causes AIDS, disproving treatment protocols based on this model, as well. A national team of AIDS researchers...

  • Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Ghate, Manisha; Tripathy, Srikanth; Gangakhedkar, Raman; Thakar, Madhuri; Bhattacharya, Jayanta; Choudhury, Ipsita; Risbud, Arun; Bembalkar, Shilpa; Kadam, Dileep; Rewari, Bharat B.; Paranjape, Ramesh // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p942 

    Background & objectives: The treatment outcomes under national antiretroviral therapy (ART) programme are being evaluated in some ART centres in the country. We carried out this study to analyze the impact of first line antiretroviral therapy in HIV infected patients attending a free ART roll...

  • MANAGEMENT OF A TREATMENT EXPERIENCED HIV PATIENT. Incze, Andrea; Chiriac, Carmen Lucia; Kezdi, Iringo Zaharia // Therapeutics, Pharmacology & Clinical Toxicology;2011, Vol. 15 Issue 2, p151 

    Treatment experienced patients had limited treatment options during the past decade. The situation has changed with the arrival of the new antiretrovirals. We describe the case of a human immunodeficiency virus (HIV) infected patient with previous therapeutic failures, low levels of T CD4+ cell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics